I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Epilepsy Research Program

Leveraging Research Award

Announcement Type: Initial

Funding Opportunity Number: HT9425-23-ERP-LRA

Assistance Listing Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Submission Deadline:** 5:00 p.m. Eastern time (ET), May 19, 2023
- **Application Submission Deadline:** 11:59 p.m. ET, June 23, 2023
- **End of Application Verification Period:** 5:00 p.m. ET, June 28, 2023
- **Peer Review:** August 2023
- **Programmatic Review:** October 2023

This program announcement must be read in conjunction with the General Application Instructions, version 800. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ................................................................. 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY .................. 3

   II.A. Program Description ........................................................................................................ 3
         II.A.1. FY23 ERP Focus Areas ........................................................................................... 3
         II.A.2. Award History ........................................................................................................ 4

   II.B. Award Information .......................................................................................................... 4

   II.C. Eligibility Information ..................................................................................................... 9
         II.C.1. Eligible Applicants .................................................................................................. 9
         II.C.2. Cost Sharing ........................................................................................................... 10
         II.C.3. Other ...................................................................................................................... 10

   II.D. Application and Submission Information ...................................................................... 10
         II.D.1. eBRAP and Grants.gov .......................................................................................... 10
         II.D.2. Content and Form of the Application Submission ................................................ 11
         II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM) ...... 26
         II.D.4. Submission Dates and Times ................................................................................. 26
         II.D.5. Funding Restrictions .............................................................................................. 27
         II.D.6. Other Submission Requirements ........................................................................... 28

   II.E. Application Review Information ................................................................................... 28
         II.E.1. Criteria ................................................................................................................... 28
         II.E.2. Application Review and Selection Process ............................................................ 31
         II.E.3. Integrity and Performance Information .................................................................. 32
         II.E.4. Anticipated Announcement and Federal Award Dates .......................................... 32

   II.F. Federal Award Administration Information .................................................................. 32
         II.F.1. Federal Award Notices ........................................................................................... 32
         II.F.2. Administrative and National Policy Requirements ................................................ 33
         II.F.3. Reporting ................................................................................................................ 34

   II.G. Federal Awarding Agency Contacts .............................................................................. 35
         II.G.1. eBRAP Help Desk ................................................................................................. 35
         II.G.2. Grants.gov Contact Center .................................................................................... 35

   II.H. Other Information .......................................................................................................... 35
         II.H.1. Program Announcement and General Application Instructions Versions .......... 35
         II.H.2. Administrative Actions ......................................................................................... 35
         II.H.3. Application Submission Checklist ......................................................................... 38

APPENDIX 1: ACRONYM LIST ........................................................................................... 40
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2023 (FY23) Epilepsy Research Program (ERP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). The ERP was initiated in 2015 to support longitudinal epidemiological research to better understand the incidence of post-traumatic epilepsy (PTE) following a traumatic brain injury (TBI) and to improve patient care and outcomes. The FY23 ERP challenges the research community to (1) investigate topics related to epileptogenesis for the identification of mechanisms by which brain injury produces epilepsy, (2) study the prevention of PTE and concomitant comorbidities, and (3) develop innovative research tools or biomarkers to better detect, diagnose, or predict the development of PTE. Appropriations for the ERP from FY15 through FY22 totaled $73.5 million (M). The FY23 appropriation is $12.0M.

The ERP encourages collaboration among PTE researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged.

_The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public._

II.A.1. FY23 ERP Focus Areas

Applications to the FY23 ERP Leveraging Research Award (LRA) should address at least one of the Focus Areas listed below. Applications may address more than one Focus Area. An application that proposes research outside of these FY23 ERP Focus Areas is also acceptable, as long as the applicant provides a strong justification as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.

- **Markers and Mechanisms:** Identifying biomarkers or mechanisms of PTE, which may include the following:
  - Predictive biomarkers of epileptogenesis (acute and chronic)
  - Research into the prevention of epilepsy and/or seizures
• **Epidemiology**: Epidemiological characterization of PTE following TBI, which may include the following:
  - Understanding and improving the quality of life of individuals with PTE, their families, and/or their care partners
  - Predictors of the development of epilepsy
  - Outcomes, including latency to and prevention of epilepsy, comorbidities, and mortality

• **Longitudinal Studies**: Studies of the evolution of PTE, which may include the following:
  - Understanding and improving the quality of life of individuals with PTE, their families, and/or their care partners
  - Treatment and healthcare outcomes research, including quality of care
  - Natural history of PTE and prognosis
  - Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)

• **Innovative Research**: Tools intended to better inform or improve upon PTE research and care, which may include the following:
  - Strategies that will improve seizure detection, characterization, visualization, or diagnosis
  - Development of new models or better characterization of existing etiologically relevant models for PTE

II.A.2. Award History

The ERP LRA mechanism is being offered for the first time in FY23.

II.B. Award Information

The intent of the FY23 ERP LRA is to leverage ongoing or completed research studies for which PTE was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of PTE. The project may include basic, translational, and/or clinical research studies. The study must be associated with an ongoing or completed research effort in which PTE is/was not a research priority and for which addition of cohorts, outcomes, assessments, or analysis specific to PTE would be scientifically justified to increase our understanding of PTE. Examples of allowable research include but are not limited to:

• Secondary analysis of epilepsy surveillance data to evaluate PTE risk
• Addition of a chronic TBI cohort in an ongoing preclinical animal study to evaluate seizure outcomes and epileptogenesis
• Recruitment of a PTE cohort within an ongoing observational longitudinal study for a known concomitant comorbidity of PTE such as depression, cognitive deficits, sleep disorder, etc.

The proposed project should not detract from the primary aims of the parent study; rather, it should complement the study by enriching the research that may be performed. The LRA may provide support for additional expertise within research teams, funds for additional experiments or assessments, support for PTE specific cohorts, etc. Projects that build a new research program or expand existing PTE-research efforts do not meet the intent of this funding opportunity.

Important aspects of this award mechanism include:

• **Preliminary data:** Preliminary research/data that is suitable for expanding into the PTE field are required. In addition, evidence demonstrating the ability of the research team to execute the chosen model of TBI and record subsequent seizure is also required, if applicable.

• **Impact:** Applications should articulate how expanding an ongoing or completed research project would be appropriate to make a short-and/or long-term impact on the PTE research field, patient care, and/or those living with PTE. Projects should address one or more of the FY23 ERP Focus Areas or provide a strong justification as to why the alternative topic is critical to advance understanding of PTE and addresses the ERP mission. Applicants are encouraged to consult with individuals living with PTE during the development and execution of the proposed research project, to ensure research outcomes maximize translational and impact potential (See Community Collaborations).

• **Relevance to Military Health:** Projects must be relevant to military Service Members, their families, and/or Veterans with PTE. Collaboration with military and VA researchers and clinicians is encouraged but not required.

• **Experience in PTE Research:** The PI on the application can be from any field or discipline; however, it is CRITICAL that the application demonstrate the study team’s experience in PTE research, including expertise in the fields of BOTH TBI and epilepsy.

**Clinical trials are not allowed under this funding opportunity.** Permitted research includes preclinical studies in animal models, observational research with human subjects, or research involving human anatomical substances or data, as well as ancillary studies associated with an existing clinical trial.

**Employing community collaborations to optimize research impact is encouraged but NOT required.** Research funded by the FY23 ERP should be responsive to the needs of people with PTE, their families, and/or their care partners. Research teams are therefore encouraged to establish and utilize effective and equitable collaborations and partnerships with community members with lived PTE experience to maximize the translational and impact potential of the proposed research.

Collaborative research approaches such as community-based participatory research, participatory action research, and integrated knowledge transition, create partnerships between scientific researchers and community members to create knowledge useable by both sets of stakeholders.
Recognizing the strengths of each partner, scientific researchers and community members **collaborate and contribute equitably** on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. **Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of community members within the research team.** Research results are jointly interpreted, disseminated, and fed back to affected communities and may be translated into interventions or policy. These methods are critically important for community-level interventions and can also have important impacts on translational research and prototype development to identify and augment the potential impact of a research program on people living with PTE, their families, and/or their care partners.

Collaborative relationships with the lived experience community are often established through integrating community members into research teams as co-researchers, advisors, and/or consultants. Some examples for implementing collaborative research approaches include:

- **Lived Experience Consultation:** The research team includes at least one project advisor with lived PTE experience who will provide advice and consultation throughout the planning and implementation of the research project. Lived Experience Consultants may include individuals with PTE, their family members, or their care partners.

- **Partnership with a community-based organization:** The research team establishes partnerships with at least one community-based organization that provides advice and consultation throughout the planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policy makers, or other formal organizational stakeholders.

- **Community Advisory Board utilization:** A community advisory board is composed of multiple community stakeholders and can take many forms, from a board of Lived Experience Consultants to a coalition of community-based organizations or any combination thereof. As with Lived Experience Consultants and organizational partners, the community advisory board provides advice and consultation throughout planning and implementation of the research project.

Additional information on collaborative research approaches can be found here:


**Experimental design should maximize rigor and reproducibility.** All projects should adhere to accepted standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Core standards are described in Landis SC, et al., A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191 (https://www.nature.com/articles/nature11556). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated direct costs budgeted for the entire period of performance for an FY23 ERP LRA Award should not exceed **$250,000**. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2024. For additional information refer to Section II.F.1, Federal Award Notices.

The CDMRP expects to allot approximately $0.80M to fund approximately two LRA applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY23 funding opportunity will be funded with FY23 funds, which will expire for use on September 30, 2029.

**Research Involving Animals:** All research funded by the FY23 ERP LRA involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO) Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of
record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions, Appendix 1, for additional information.

**Research Involving Human Data, Human Anatomical Substances, Human Subjects, or Human Cadavers:** All DOD-funded research involving new and ongoing research with human data, human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC OHARO, Office of Human Research Oversight (OHRO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of application submission is not required; however local IRB/EC approval is necessary prior to OHRO review. Allow up to 3 months to complete the OHRO regulatory review and approval process following submission of all required and complete documents to the OHRO. Refer to the General Application Instructions, Appendix 1, and the OHARO web page, https://mrdc.health.mil/index.cfm/collaborate/research_protections/hrpo, for additional information.

As of January 20, 2020, U.S. institutions engaged in non-exempt cooperative research must rely on a single IRB to review and approve the portion of the research conducted at domestic sites in accordance with Code of Federal Regulations, Title 45, Part 46.114(b) (45 CFR 46.114[b]). If the proposed, non-exempt research involves more than one U.S.-based institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.

**Clinical trials are not allowed under this funding opportunity.** As stated in Section II.H.2.c, Withdrawal, applications including a clinical trial as any part of the application may be administratively withdrawn. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

Clinical research is allowed within this funding opportunity and encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects, but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to
study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. **Note:** Studies that meet the requirements for exemption under §.104(d)(4) of the Common Rule are not considered clinical research as defined by CDMRP. Exemption category 4 refers to secondary research for which consent is not required.

**Use of DOD or VA Resources:** If the proposed research involves access to active-duty military and/or VA patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix I, for additional information.

**The Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System:** The DOD requires that awardees make TBI research data generated by this award mechanism available to the research community through the FITBIR Informatics System. The FITBIR Informatics System is a free resource designed to accelerate research progress by allowing the storage, reanalysis, integration, and rigorous comparison of multiple datasets. **Currently, FITBIR-eligible research includes all studies generating prospectively collected human TBI subject data (e.g., clinical, demographic, phenotypic, imaging, genomic).** Data reporting to FITBIR is an opportunity for investigators to facilitate their own research and to collaborate with others engaged in similar research. While there is no direct charge to users of the FITBIR Informatics System, a project estimation tool ([https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp](https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp)) is available to help estimate costs and manpower needs that may be associated with data submission. FITBIR guidance and policies, as well as the considerable advantages of FITBIR participation to the researcher, are detailed at [https://fitbir.nih.gov/](https://fitbir.nih.gov/).

**II.C. Eligibility Information**

**II.C.1. Eligible Applicants**

**II.C.1.a. Organization:** All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

**Government Agencies Within the United States:** Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

**Extramural Organization:** An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD, and research institutes.
**Intramural DOD Organization:** A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. **Intramural Submission:** An application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

- The named Principal Investigator (PI) may be an investigator at any career level.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

The CDMRP strongly encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at [https://orcid.org/](https://orcid.org/).

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

II.D.1. eBRAP and Grants.gov

The electronic Biomedical Research Application Portal (eBRAP) ([https://ebrap.org](https://ebrap.org)) is a secure web-based system that allows PIs to submit their pre-applications, view and verify extramural full applications submitted to Grants.gov ([https://grants.gov](https://grants.gov)), receive communications from the CDMRP, and submit documentation during award negotiations and
throughout the period of performance. eBRAP also allows intramural organizations to submit full applications following pre-application submission.

**Grants.gov** is a federal system required to be utilized by agencies to receive and process extramural grant applications. Full applications may only be submitted to Grants.gov after submission of a pre-application through eBRAP.

Contact information for the eBRAP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

**Extramural Submission:**
- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

**Intramural DOD Submission:**
- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

*Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.*

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1, Full Application Guidelines).

*The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process.* Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

*During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.*

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. *Incorrect selection of extramural or intramural submission type will delay processing.*
If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/).

The applicant organization and associated PI identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**
  
  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**
  
  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

  Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

  It is recommended that applicants identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**
  
  Enter the name, organization, and role of all collaborators and key personnel associated with the application, including any PTE Lived Experience Consultants or representatives of community-based organizations involved in the project.
**FY23 ERP Programmatic Panel members** should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

**Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted. Include the Focus Area under which the application will be submitted. Research outside of the **FY23 ERP Focus Areas** is acceptable.

LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions. *An invitation to submit a full application is NOT provided after LOI submission and applicants are not required to have such an invitation in order to proceed to submitting a full application.*

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application to be accepted and processed.

**II.D.2.b. Step 2: Full Application Submission Content**

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

**II.D.2.b.i. Full Application Guidelines**

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader must be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the *same version* of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause
submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

*Do not password protect any files of the application package, including the Project Narrative.*

**Table 1. Full Application Submission Guidelines**

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DOD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td>Download application package components for HT9425-23-XXRP-XX from Grants.gov (<a href="https://grants.gov">https://grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</td>
</tr>
<tr>
<td><strong>Full Application Package Components</strong></td>
<td>Download application package components for HT9425-23-XXRP-XX from eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</td>
</tr>
<tr>
<td><strong>SF424 Research &amp; Related Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td>Tab 1 – Summary: Provide a summary of the application information.</td>
</tr>
<tr>
<td>Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
<td>Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
<tr>
<td>Descriptions of each required file can be found under Full Application Submission Components:</td>
<td>Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</td>
</tr>
<tr>
<td>- Attachments</td>
<td>- Attachments</td>
</tr>
<tr>
<td>- Research &amp; Related Personal Data</td>
<td>- Key Personnel</td>
</tr>
<tr>
<td>- Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>- Budget</td>
</tr>
<tr>
<td>- Research &amp; Related Budget</td>
<td>- Performance Sites</td>
</tr>
<tr>
<td>- Project/Performance Site Location(s) Form</td>
<td>Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</td>
</tr>
<tr>
<td>- Research &amp; Related Subaward Budget Attachment(s) Form</td>
<td></td>
</tr>
</tbody>
</table>
### Extramural Submissions

**Application Package Submission**

- **Create a Grants.gov Workspace.** Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.

- **Submit a Grants.gov Workspace Package.** An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package at least **24-48 hours prior to the close date** to allow time to correct any potential technical issues that may disrupt the application submission.

  **Note:** If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID **prior to** the application submission deadline. **Do not password protect any files of the application package, including the Project Narrative.**

<table>
<thead>
<tr>
<th>Application Verification Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified <strong>with the exception of the Project Narrative and Research &amp; Related Budget Form.</strong></td>
</tr>
</tbody>
</table>

### Intramural DOD Submissions

- **Submit package components to eBRAP ([https://ebrap.org](https://ebrap.org)).**

- **Tab 5 – Submit/Request Approval Full Application:** After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email. **Do not password protect any files of the application package, including the Project Narrative.**

<table>
<thead>
<tr>
<th>Application Verification Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified <strong>with the exception of the Project Narrative and Research &amp; Related Budget Form.</strong> Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.</td>
</tr>
</tbody>
</table>
The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

- Extramural Applications Only

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.

- Extramural and Intramural Applications

  Attachments:

  *Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.*

  For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 megabytes (MB), and the file size for the entire full application package may not exceed 200 MB.

  - **Attachment 1: Project Narrative (15-page limit):** Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.
Describe the proposed project in detail using the outline below.

- **Parental Study**: Describe the research effort to be leveraged in the proposed study with enough detail to articulate the overarching goals and scientific approach of the ongoing/completed effort. PTE should not be an existing research priority for the parental study. Describe any research products to be leveraged in the proposed research including preclinical/clinical cohorts, data, biospecimens, or research resources/tools. If applicable, indicate the size of the pre-existing cohort/data set, including subjects and controls, and the expected statistical power as it relates to the proposed study.

- **Background**: Present the ideas and scientific reasoning behind the proposed research project that will leverage the parental study. Clearly demonstrate that there is sufficient scientific evidence to support the proposed stage of research, including preliminary and/or published data. Cite relevant literature. Describe previous experience most pertinent to this project.

- **Hypothesis or Objectives**: State the hypothesis (or hypotheses) or objectives to be tested in the proposed project.

- **Specific Aims**: Concisely explain the project’s specific aims. Describe only aims that this ERP award would fund.

- **Focus Area**: Describe how the work aligns to one of the FY23 ERP Focus Areas, or if the work does not align to an FY23 ERP Focus Area, explain the critical research area the application will address and its relevance to the ERP mission. An application that proposes research outside of the FY23 ERP Focus Areas is acceptable, as long as a strong justification is provided as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.

- **Study Design and Feasibility**: Describe the research strategy, methods, and analyses, including appropriate controls, in sufficient detail for evaluation of appropriateness and feasibility. Describe how the proposed study is designed to achieve the LRA specific aims. Address potential problem areas and present alternative methods and approaches.

  Explain how the existing research effort will be leveraged and expanded to support the proposed study objectives, and indicate how the changes to the parental study (e.g., additional cohorts, outcomes, assessments, analysis) will increase our understanding of PTE. Clearly articulate how expansion of the parental study into the PTE research space would be feasible and complimentary to the research already performed.

Describe the statistical plan as appropriate for the proposed research.

If applicable, briefly describe the development and use of animal model(s) including a rationale for the choice of animal model, injury method, and endpoints/outcome measures to be used. Full details will be required in the Animal Research Plan (Attachment 8). If an animal model of TBI will be employed, provide evidence that
demonstrates the research team’s ability and capacity to execute the chosen model of TBI and record subsequent seizure.

If human subjects, human anatomical samples or data will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples or data. Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, racial, and ethnic group, and an accompanying rationale for the selection of subjects. If active-duty military, Veteran, or military family member population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed research, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population.

Clinical trials are disallowed in this mechanism.

If the research proposed is epidemiologic in nature, describe how the research will be conducted in accordance with the 2011 International League Against Epilepsy research guidelines for epidemiologic studies and surveillance of epilepsy found at https://www.ncbi.nlm.nih.gov/pubmed/21899536.

- Research Team Composition: Describe the composition of the research team including how/whether the research team from the parental study will change to support expansion into the PTE field. Provide enough detail to demonstrate the study team’s experience in PTE research, including expertise in the fields of BOTH TBI and epilepsy.

- Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional
facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents**: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support (three-page limit per letter)**: Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration (if applicable) (three-page limit per letter)**: Provide a signed letter from each collaborating individual or organization demonstrating that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

- **Intellectual Property**: Information can be found in the 2 CFR 200.315, “Intangible Property.”
  - **Intellectual and Material Property Plan (if applicable)**: Provide a plan for resolving intellectual and material property issues among participating organizations.
  - **Commercialization Strategy (if applicable)**: Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- **Data Management Plan (2-page limit)**: If there is a separate Data Management Plan attachment, then submission of the Data Management Plan under “Supporting Documentation” is not required. Describe the data management plan in accordance with Section 3.c., Enclosure 3, DoD Instructions 3200.12.
  - For Extramural Applications: Refer to General Application Instructions, Section III.A.2, Attachments Form, Attachment 2, Supporting Documentation, for more detailed information.
- For Intramural Applications: Refer to General Application Instructions, Section IV.A.1, Application Component – Attachments, Attachment 2, Supporting Documentation, for more detailed information.

- **Inclusion Enrollment Plan (only required if clinical research is proposed):** Provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Public Health Service (PHS) Inclusion Enrollment Report is a three-page fillable PDF form, which can be downloaded from eBRAP at [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm).

- **Use of DOD Resources (if applicable):** Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.

- **Use of VA Resources (if applicable):** Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

  - **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. **Do not include proprietary or confidential information.** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Technical abstracts should be written using the outline below. The technical abstract should provide an appropriate description of the project’s key aspects; clarity and completeness within the space limits of the technical abstract are highly important.

  - **Background:** Present the ideas and reasoning behind the proposed project including a brief description of the ongoing or completed research project to be leveraged in this study.

  - **Hypothesis or Objectives:** State the hypothesis (or hypotheses) or objectives to be tested.

  - **Specific Aims:** State the specific aims of the proposed research project.

  - **Study Design:** Briefly describe the study design.

  - **Impact:** Briefly describe the short- or long-term impact of this study on PTE research, patient care, and/or quality of life. Indicate how the proposed research could benefit the military and/or Veteran populations.
Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”. The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Do not duplicate the technical abstract. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Minimize use of acronyms and abbreviations, where possible. The lay abstract is an important component of the application review process because it addresses issues of particular interest to people living with PTE. Do not duplicate the technical abstract.

- Describe the objectives and rationale for the proposed research in a manner that will be readily understood by readers without a background in science or medicine.

- Describe the ultimate applicability and impact of the research to people living with PTE.
  - What populations will it help, and how will it help them?
  - What are the potential applications, benefits, and risks?
  - What is the projected time it may take to achieve a person-related outcome?
  - If the research is too basic for immediate clinical applicability, describe the interim outcomes.
  - What are the likely contributions of the proposed research project to advancing PTE research, patient care, and/or quality of life?

Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”. The suggested Statement of Work (SOW) format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” webpage (https://ebrap.org/eBRAP/public/Program.htm). Recommended strategies for assembling the SOW can be found at https://ebrap.org/eBRAP/public/Program.htm.

For the FY23 ERP LRA mechanism, refer to the “Suggested SOW Strategy Generic Research” document for guidance on preparing the SOW and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

- FITBIR-eligible research should also include the following subtasks:
  - FITBIR investigator and study registration within the first 30 days of the award
  - Sharing of draft data collection forms with FITBIR
  - Annual FITBIR data submissions
Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”. This attachment should be written with a broad audience in mind, including readers without a background in science or medicine.

Address the impact of the proposed research on one or more of the FY23 ERP Focus Areas or an alternative topic critical to advance understanding of PTE. Describe the short- and long-term impact of this study on PTE research, patient care, and/or quality of life, including an assessment of the likelihood that a successful outcome of the proposed research project will increase our understanding of PTE and/or lead to a practical application in individuals living with PTE. Indicate how the proposed research project is applicable to the healthcare needs and quality of life of injured military Service Members, Veterans, and/or their family members, or care partners.

Attachment 7: Data and Research Resource Sharing Plan (two-page limit): Upload as “Sharing.pdf”. Describe the type of data or research resource to be made publicly available as a result of the proposed work. Describe how data and resources generated during the performance of the project will be shared with the PTE research community. Include the name of the repository(ies) where scientific data and resources arising from the project will be archived, if applicable. If a public repository will not be used for data or resource sharing, provide justification. Provide a milestone plan for data/results dissemination including when data and resources will be made available to other users, including dissemination activities with a particular focus on feeding back the data to affected communities and/or research participants. If applicable, identify and describe the planned National Institute of Neurological Disorders and Stroke TBI and/or Epilepsy Common Data Elements (CDEs) to be used/colllected.

For additional guidance regarding sharing of data and research resources, refer to the General Application Instructions, Appendix 2, Section K.

Attachment 8: Animal Research Plan (three-page limit): Upload as “AnimalResPlan.pdf”. (Attachment 8 is only applicable and required for applications proposing animal studies.) If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the IACUC. The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology. Be specific as to why an animal model is necessary to address the study aims, why the specific animal and injury model were chosen over other models, and how they are optimal for addressing the study aims.

- Summarize the procedures to be conducted. Describe how the study will be controlled.
Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.

Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

Attachment 9: Collaborative Research Plan: Upload as “Collaboration.pdf”. (Attachment 9 is only applicable for applications utilizing a collaborative research approach that engages the PTE lived experience community, and/or PTE community-based organization[s].)

Collaborative Research Statement (three-page limit): For the FY23 ERP, it is encouraged that research teams establish and utilize effective and equitable collaborations and partnerships with the PTE lived experience community to maximize the translational and impact potential of proposed research. More detailed description and expectations of these collaborations/partnerships is included in the Community Collaboration section above. If a partnership with the PTE lived experience community will be utilized (e.g., PTE Lived Experience Consultation, partnership with a community-based organization) include the community partner’s name and describe the following as applicable.

- The collaborative research approach that will be used (e.g., Lived Experience Consultation, partnership with community-based organization, community advisory board, co-researcher model) including a justification for the approach as well as when the approach will be used within the research project.

- The input that will be captured and how this input will be meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and/or dissemination of the research.

- The resource allocation and decision-making processes to be employed.

- Any training that will be provided to both scientific researchers and community members on collaborative research approaches, decision-making, and equitable participation.

- Co-learning and capacity-building activities among all partners.

- The process measures to assess the effectiveness of the chosen collaborative research approach.
Letters of Community Collaboration, (two-page limit per letter): Provide a letter signed by each Lived Experience Consultant or community-based partner confirming their role and commitment to participate on the research team. If a community-based organization will be engaged, the letter of commitment should be signed by BOTH the organization point of contact leading the engagement along with the organization’s leadership endorsing the collaboration. The letter should include the qualifications and background of the Lived Experience Consultant(s), community-based partner, and/or organization point of contact and describe the relevance of those qualifications to the proposed research project.

Attachment 10: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

Attachment 11: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

Extramural and Intramural Applications

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681[a] et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.
○ PI Biographical Sketch (six-page limit): Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

○ PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
  – For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
  – For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

○ Key Personnel Biographical Sketches (six-page limit each): Upload as “Biosketch_LastName.pdf”.
  – If applicable, biographical sketches, or an equivalent document, should also be included for community partners (e.g., Lived Experience Consultant, representative of community-based organization) to demonstrate background and experience relevant to their role in the proposed research project.

○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
  – For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
  – For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.
• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

○ Intramural DOD Collaborator(s): Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 11. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)

The applicant organization must be registered as an entity in SAM (https://www.sam.gov/SAM/) and receive confirmation of an “Active” status before submitting an application through Grants.gov. As of April 2022, all federal awards including, but not limited to, contracts, grants, and cooperative agreements will use the UEI generated through SAM.gov. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the
application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

The maximum period of performance is 3 years.

The application’s direct costs budgeted for the entire period of performance should not exceed $250,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

For this award mechanism, direct costs must be requested for:

- **Interim (In-Progress) Review (IPR):** Travel costs for the PI to present project information or disseminate project results at a DOD ERP In-Progress Review meeting during the period of performance. For planning purposes, it should be assumed that the meeting will be held during year 2 of the award in the National Capital Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.
May be requested for (not all-inclusive):

- Data and research resource sharing costs
- Costs associated with collaborative research approach (e.g., consultant costs, equitable participation training, capacity-building activities)
- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the IPR meeting described above. The intent of travel costs to scientific/technical meetings is to present project information or disseminate project results from the FY23 ERP LRA.

Must not be requested for:

- Clinical trial costs

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in decreasing order of importance:

- **Research Strategy and Feasibility**
  - Whether the proposed research will leverage an on-going or completed research effort for which PTE was not originally a research priority.
  - To what extent the plan to expand the pre-existing research effort is feasible, scientifically justified, and supports the proposed study objectives.
○ How well the ideas and scientific reasoning support the proposed research project and demonstrate sufficient evidence to support moving into the proposed stage of research.

○ How well the hypothesis or objectives, research strategy, methods, and analyses are developed and support successful completion of the project aims.

○ How well the application acknowledges potential problems and addresses alternative approaches.

○ How well the study is designed to achieve the research objectives, including, if applicable, the development and use of animal model(s) and to what extent the chosen animal, injury method, and endpoints/outcome measures are justified.

○ Whether the statistical plan is appropriate for the proposed research.

○ If applicable, how well the application describes TBI or epilepsy CDEs to be collected and whether those CDEs are appropriate.

○ If applicable, whether the application includes sufficient evidence to support successful recruitment of and access to human subjects, data, and samples and whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.

○ If applicable, to what extent the application demonstrates the research team’s ability and capacity to execute the chosen model of TBI and record subsequent seizure.

○ If applicable, how well the study is designed to achieve reproducible and rigorous results, including controls, sample size estimation, blinding, randomization, and data handling.

- Impact

○ To what extent the proposed study addresses one or more of the FY23 ERP Focus Areas or provides a strong justification as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.

○ How likely the short- and long-term impact of this study will make significant contributions on PTE research, patient care, and/or quality of life.

○ How likely a successful outcome of the efforts will increase our understanding of PTE and/or lead to a practical application in individuals living with PTE.

○ To what degree the research addresses questions related to the healthcare needs and quality of life of injured military Service Members, Veterans, and/or their family members, as well as their care partners.

○ If a collaborative research approach that engages the PTE lived experience community, and/or PTE community-based organization(s) will be employed, how well the input of community members will be captured and to what extent this input will be
meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and/or dissemination of the research.

- **Personnel**
  - To what extent the study team’s background and experience are appropriate to accomplish the proposed research project, including the expansion of a pre-existing research effort into the PTE field.
  - How well the composition of the study team demonstrates expertise in *BOTH* TBI and epilepsy.
  - To what degree the levels of effort are appropriate to ensure successful conduct of the proposed work.
  - *If a collaborative research approach that engages the PTE lived experience community, and/or PTE community-based organization(s) will be employed*, to what degree the qualifications and background of the Lived Experience Consultant(s), community-based partner(s), and/or organization point of contact are relevant to the proposed research project.

In addition, the following **unscored criteria** will also contribute to the overall evaluation of the application:

- **Data and Research Resource Sharing Plan**
  - Whether project data and research resources will be shared with the PTE research community.
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable. If applicable, whether one or more specific repositories are named where scientific data and resources arising from the project will be archived.
  - Whether data and outcome dissemination activities, with particular focus on feeding back the data to affected communities, is described and appropriate.

- **Budget**
  - Whether the direct costs exceed the allowable direct costs as published in the program announcement.
  - Whether the budget is appropriate for the proposed research.

- **Environment**
  - To what extent the scientific environment is appropriate for the proposed research project.
○ How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).

○ To what extent the quality and level of institutional support are appropriate for the proposed research project.

- Application Presentation

○ To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers

- Relevance to the mission of the Defense Health Program and FY23 ERP, as evidenced by the following:
  ○ Adherence to the intent of the award mechanism
  ○ Relevance to military health
  ○ Program portfolio composition
  ○ Relative impact

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.health.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the ERP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and
evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY23 funds are anticipated to be made no later than September 30, 2024. Refer to the General Application Instructions, Appendix 2, for additional award administration information.
After email notification of application review results through eBRAP, and if selected for funding, a representative from the USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

**Pre-Award Costs:** An institution of higher education, hospital, or non-profit organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

*Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds.* No commitment on the part of the government should be inferred from discussions with any other individual. **The award document signed by the Grants Officer is the official authorizing document.**

**Federal Government Organizations:** Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

**II.F.1.a. PI Changes and Award Transfers**

Unless otherwise restricted, changes in PI or organization will be allowed at the discretion of the USAMRAA Grants Officer, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

**II.F.2. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D General Terms and Conditions and the USAMRAA General Research Terms and Conditions: Addendum to the DoD R&D General Terms and Conditions for further information.
Certification Regarding Disclosure of Funding Sources. The proposing entity must comply with Section 223(a) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, which requires that the PI, Partnering PIs (if applicable), and all key personnel:

- Certify that the current and pending support provided on the application is current, accurate, and complete;
- Agree to update such disclosure at the request of the agency prior to the award of support and at any subsequent time the agency determines appropriate during the term of the award; and
- Have been made aware of the requirements under Section 223(a)(1) of this Act.

False, fictitious, or fraudulent statements or claims may result in criminal, civil, or administrative penalties (18 USC 1001).

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.

Annual progress reports and quad charts as well as a final progress report and quad chart will be required.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

PHS Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).
II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the eBRAP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET (closed on most U.S. federal holidays). Response times may vary depending upon the volume of inquiries.

   Phone:  301-682-5507
   Email:  help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the eBRAP Help Desk is unable to provide technical assistance with Grants.gov submission.

   Phone:  800-518-4726; International 1-606-545-5035
   Email:  support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 800c. The program announcement numeric version code will match the General Application Instructions version code 800.

II.H.2. Administrative Actions

After receipt of applications, the following administrative actions may occur:
II.H.2.a. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY23 ERP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY23 ERP Programmatic Panel members can be found at https://cdmrp.health.mil/erp/panels/panels23.

- The application fails to conform to this program announcement description.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY23, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.health.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.
• Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• A clinical trial is proposed.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
## II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SF424 Research &amp; Related Application for Federal Assistance</strong> &lt;br&gt; <em>(extramural submissions only)</em></td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td><strong>Summary (Tab 1) and Application Contacts (Tab 2)</strong> &lt;br&gt; <em>(intramural submissions only)</em></td>
<td>Complete tabs as instructed</td>
<td></td>
</tr>
<tr>
<td><strong>Attachments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 6 with file name “Impact.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data and Research Resource Sharing Plan: Upload as Attachment 7 with file name “Sharing.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Research Plan: Upload as Attachment 8 with file name “AnimalResPlan.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collaborative Research Plan: Upload as Attachment 9 with file name “Collaboration.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Representations (extramural submissions only): Upload as Attachment 10 with file name “RequiredReps.pdf”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 11 with file name “MFBudget.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Personal Data</strong></td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Completed</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field</td>
<td></td>
</tr>
<tr>
<td>Budget (intramural submissions only)</td>
<td>Suggested DOD Military Budget Format, including justification</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form, if applicable</td>
<td>Complete form as instructed</td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
</tr>
<tr>
<td>ACURO</td>
<td>Animal Care and Use Review Office</td>
</tr>
<tr>
<td>CDE</td>
<td>Common Data Elements</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ERP</td>
<td>Epilepsy Research Program</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IPR</td>
<td>In-Progress Review</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LIMBIC-CENC</td>
<td>Long-Term Impact of Military Relevant Brain Injury Consortium- Chronic Effects of Neurotrauma Consortium</td>
</tr>
<tr>
<td>LOI</td>
<td>Letter of Intent</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MB</td>
<td>Megabytes</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>OHARO</td>
<td>Office of Human and Animal Research Oversight (previously Office of Research Protections)</td>
</tr>
<tr>
<td>OHRO</td>
<td>Office of Human Research Oversight (previously Human Research Protection Office)</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>PDF</td>
<td>Portable Document Format</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PTE</td>
<td>Post-Traumatic Epilepsy</td>
</tr>
<tr>
<td>P-TERC</td>
<td>Post-Traumatic Epilepsy Research Center</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>STEM</td>
<td>Science, Technology, Engineering, and/or Mathematics</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic Brain Injury</td>
</tr>
<tr>
<td>TRACK-TBI</td>
<td>Transforming Research and Clinical Knowledge in TBI</td>
</tr>
<tr>
<td>UEI</td>
<td>Unique Entity Identifier</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>Department of Veterans Affairs</td>
</tr>
</tbody>
</table>